GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.

NXP800 yields neither severe thrombocytopenia, nor any responses.

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.